Anika Q2 2023 Earnings Report
Key Takeaways
Anika Therapeutics reported strong second-quarter results, with double-digit revenue growth driven by OA Pain Management. The company is making significant progress with its Hyalofast Phase III trial and advancing the development of Integrity. Anika updated its full-year revenue outlook to $159.5 million to $163 million.
Anika reported double-digit top line growth and improved margins in Q2 2023.
The Phase III Pivotal study for Hyalofast is fully enrolled and on track for modular PMA filing.
Development of Integrity, the HA-based rotator cuff patch system, remains on track for a 2024 launch.
RevoMotion™ Reverse Shoulder full market release accelerated to September 2023.
Anika
Anika
Forward Guidance
Anika expects full-year 2023 revenue to be between $159.5 million and $163 million, representing growth of 2% to 4% compared to 2022.